Department of Psychiatry

Penn Behavioral Health

Current Study Listings

We currently have many research studies offering treatments for individuals who have symptoms of depression.

Medication-Based Studies

Several of our medication-based studies are exploring the use of a new medication in combination with an already prescribed antidepressant medication. These studies are for individuals who have not received enough benefit from the antidepressant medications that they are currently taking.

Close

A Relapse Prevention Study Evaluating the Efficacy of Vortioxetine in Adults with Major Depressive Disorder

This study is being conducted to evaluate the long-term maintenance effects of individuals treated with vortioxetine (aka, Brintellix) in the prevention of depression relapse. Participants will be enrolled into a 8-16 weeks open-label treatment period. During the open-label period, all subjects will receive 10 mg Vortioxetine. At the end of the open label patients have option to go into 16 -52 week, double blind study to assess the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults with MDD.

Participate

Close

401 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.

  • The 401 Study is a randomized, double-blind, placebo-controlled  research study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression.

You may be able to take part in the 401 or 402 Study if you:

  • are between 18 and 65 years of age (inclusive)
  • have been diagnosed with bipolar I or bipolar II disorder
  • are currently having a major depressive episode that started at least 2 weeks ago, but no more than
    6 months ago
  • have previously had at least one bipolar manic episode or mixed episode (if you have bipolar I disorder) or hypomanic episode (if you have bipolar II disorder).

Study participation will last up to 12 weeks and will require nine visits to the study center.

Participate

Close

402 Study: Trial of Assessing the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

We are looking for people who are currently experiencing major depressive episodes associated with bipolar I or bipolar II disorder to take part in our bipolar depression studies. These clinical research studies are designed to help us learn more about an investigational medication for symptoms of bipolar depression.

  • The 402 study is a randomized, double-blind, placebo-controlled research study which is looking at whether an investigational medication, called ITI-007, can improve the symptoms of bipolar depression (bipolar I or bipolar II disorder). It also aims to look at how safe the investigational medication is and whether it impacts the quality of life and well-being of people with bipolar depression, when it is added to existing treatment with a mood stabilizer, specifically lithium or valproate.

You may be able to take part in the 401 or 402 Study if you:

  • are between 18 and 65 years of age (inclusive)
  • have been diagnosed with bipolar I or bipolar II disorder
  • are currently having a major depressive episode that started at least 2 weeks ago, but no more than
    6 months ago
  • have previously had at least one bipolar manic episode or mixed episode (if you have bipolar I disorder) or hypomanic episode (if you have bipolar II disorder).

Study participation will last up to 12 weeks and will require nine visits to the study center.

Participate

Close

Comparing Effectiveness of Aripiprazole Augmentation, rTMS Augmentation, and Switching to Venlafaxine XR in Treatment Resistant Depression (ASCERTAIN-TRD)

We are looking for people who are currently experiencing major depressive episode to take part in this depression study. This clinical research study is designed to help us learn more about the efficacy of three treatment options for depression.

  • The ASCERTAIN-TRD study is a multi-site, randomized, open-label study to compare the efficacy of  a) aripiprazole added to the current antidepressant, b) rTMS added to the current antidepressant, and c) switching to venlafaxine XR.

You may be able to take part in this study if you:

  • are between 18 and 80 years of age (inclusive)
  • have been diagnosed with major depressive disorder
  • are currently experiencing depressive symptoms
  • are currently on an antidepressant medication but haven’t experienced at least 50 % improvement in your symptoms
  • have tried at least 1 other antidepressant medication but did not experience at least 50 % improvement in your symptoms

The study doctor will discuss additional requirements for being in the study with you.

Study participation will last up to 12 weeks and will require visits to the study center.

Participate

Close

A Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder

We are looking for people who are currently experiencing major depressive episode to take part in this depression study. This clinical research study is designed to help us learn more about the efficacy of pimavanserin in treatment of depression.

  • This study is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotoninnorepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder who had inadequate response to antidepressant therapy.

You may be able to take part in this study if you:

  • are 18 years and older (inclusive)
  • have been diagnosed with major depressive disorder
  • are currently experiencing depressive symptoms
  • are currently taking one of the following SSRI or SNRIs without experiencing at least 50 % improvement in your symptoms: "Citalopram, Escitalopram, Paroxetine, Fluoxetine, Sertraline, Duloxetine, Venlafaxine, Desvenlafaxine, Venlafaxine"

The study doctor will discuss additional requirements for being in the study with you.

Study participation will last up to 17 weeks and will require visits to the study center.

Participate

Close

A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder

We are currently enrolling participants for a clinical research study to look at the effectiveness and safety of an investigational medication AXS-05 (a combination of bupropion and dextromethorphan) compared to bupropion (Approved by FDA), in patients with depression who have not responded to prior treatment with at least one antidepressant.

Study participation will last up to 14 weeks which will include 2 weeks screening period, 6 weeks open label period (all the patients will receive bupropion), and 6 weeks double blind period (randomized either to bupropion or study medication).

You may be able to take part in this study if you are:

  • Between 18 and 65 years of age 
  • Diagnosed with depression
  • Experiencing depression symptoms despite having taken one or two antidepressant medications in the past
  • Able to provide written consent to participate in the study

The study doctor will discuss additional requirements for being in the study with you. If you are eligible for this study and choose to participate, you will receive all study visits and study-related medical care at no cost to you. Compensation for your time and travel may also be provided.

Participate

 

Close

How to Participate in These Studies

In order for you to participate, you must first complete a pre-screen set of questionnaires to determine if you might benefit from one of these studies. You may complete this screening online by clicking here or you may call us at 215-898-4301 to complete a pre-screen telephone interview. Once this is completed, a study coordinator will either schedule you with one of our doctors or refer you to a more suitable treatment center.

If you do not qualify for one of our research studies now, we will keep your information so that we may contact you in the future about new studies.

We also collaborate on the following studies:

  • The Behavioral Sleep Medicine Program treats and studies sleep disorders, primarily insomnia.  We provide not only the highest standard of care for Insomnia (both with cognitive behavioral treatment of insomnia, CBT-I, and/or Pharmacotherapy) but also provide for a full spectrum of non-drug interventions for most of the non-medical sleep disorders.  For more information visit: http://www.med.upenn.edu/bsm.html or call 215-7-insomn (215-746-7666)
     
  • Mindfulness and Cognitive Therapy: We also collaborate with psychologists who are exploring the use of mindfulness in the treatment of acute health problems, depression and anxiety.

For more information or to schedule an appointment, please call us at 215-898-4301.


Back to Top